Bertrand Tombal, MD, PhD, Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium, provides an overview of a tolerability and pharmacokinetic analyses of combination therapy with darolutamide, androgen-deprivation therapy, and docetaxel in patients with metastatic hormone sensitive prostate cancer (mHSPC) from the Phase III ARASENS (NCT02799602) trial. The trial observed there was no added toxicities with the addition of dialuramide to docetaxel. This interview took place at the EAU congress in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.